NEW YORK (GenomeWeb News) – Epigenomics announced today that Swiss Life will provide insurance coverage for the firm's Epi proColon 2.0 colorectal cancer test as part of a preventive health program in France.

Swiss Life, France's third-largest private health insurer, is the first French insurer to cover the test, which uses Epigenomics' colorectal cancer biomarker Septin9 in blood plasma, and will reimburse for the test at up to 50 percent of the cost. French Social Security does not cover Epi proColon 2.0, Berlin-based Epigenomics noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.